The Inserm spinout secured a $7.8m series B extension and boosted its portfolio with the acquisition of AVCare, a Satt Ouest Valorisation-allied business.

Acticor Biotech, a France-based acute thrombotic disease therapeutics spinout of research institute Inserm, closed a €22.3m ($24.7m) series B round yesterday with a $7.8m extension led by regional investment unit Go Capital.
The extension also featured life sciences-focused venture fund Newton Biocapital, VC firm CapDecisif Management and investment platform Anaxago, adding to an initial $17m series B sum announced in October 2018.
Newton BioCapital led the initial tranche with participation from financial services firm Mirae Asset Capital, CapDecisif…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?